Dr. John Cush RheumNow
1 year 1 month ago
Claims data study of 82 399 PsA pts - 542 on combo targeted Rx >3 mos (200 > 6mos). 2 most common combos of apremilast w/ TNFi or IL-17i. Use of combo targeted Tx was not assoc. w/ more serious infxn (RRs 0.53; 0.17-1.63) or opportunistic infx (RR 1.00; 0.09-11.02) @ 3 or 6 mos https://t.co/mkvq1lqt9Y
Dr. John Cush RheumNow
1 year 1 month ago
RCT of 2331 chronic MSK pain pts showed that telehealth Cognitive behavioral therapy (CBT) (health coach) superior to self-care (Pain trainer) or usual care at achieving a >30% reduction in pain (32% vs 26.6% vs 20.8% respectively) & benefits were sustained at 12 months. https://t.co/a69zPsJslH
A long-term cohort study of children diagnosed with Kawasaki disease (KD) shows evidence of future adult cardiovascular complications and hospitalizations. These severe cardiovascular events clustered during the young KD adults and later, a second surge in their late 30s.
Dr. John Cush RheumNow
1 year 1 month ago
The global autoimmune disease treatment market was valued at $7 billion USD in 2024 and is expected to rise to ~$11 billion by 2030 and reach $12.6 billion by 2032 https://t.co/C5IQ0hUvQE https://t.co/RjbMo5cCOl
Treating psoriatic arthritis (PsA) patients with more than one targeted therapy appears to be just fine, with no increased risk of serious infections, insurance claims data indicate.
Aravind Palraj Rheumat_Aravind
1 year 1 month ago
Clinical Rheumatology Thread for Busy GPs:
Post 1
Early inflammatory arthritis(IA): the 3–3–3 rule
•Onset ≤3 months
•Morning stiffness ≥30–60 minutes
•≥3 swollen joints (MCP/MTP common)
If present, manage as IA: urgent rheum referral; NSAIDs if no contraindications. https://t.co/hcoumX1ZVY
The third survey in this series addressed clinician views on future trends (AI), future therapies and lessons learned.This survey captured 233 responses from rheumatologists (91), most (61%) from the USA. US respondents were from the Southeast (17.5%), Southwest (11.4%), Mid-Atlantic (9.6%) or Western (9.6%) states.
Dr. John Cush RheumNow
1 year 1 month ago
TNF Inhibitors in Takayasu's Arteritis
A large, retrospective, multicenter study demonstrated the efficacy of intravenous infliximab and subcutaneous adalimumab in patients with Takayasu arteritis.
https://t.co/lJbvaYnylO https://t.co/uRBruhW2Fd
sergio serrano belmar sserranobmsk
1 year 1 month ago
Tarsal Tunnel Syndrome: An Ultrasound Pictorial Review
https://t.co/Qr4ehZo41p
Tarsal tunnel syndrome (TTS) is an entrapment neuropathy caused by compression of the posterior tibial nerve or its branches as they pass beneath the flexor retinaculum at the medial ankle. Clinical https://t.co/FivPCl7EvU
Dr. John Cush RheumNow
1 year 1 month ago
Guidance on aromatase inhibitor-associated bone loss with hormone-sensitive breast cancer
An updated joint position statement on the management of aromatase inhibitor-associated bone loss (AIBL) addresses the heightened fracture risk in women undergoing endocrine therapy for https://t.co/ZkvToBBGdB
Dr. John Cush RheumNow
1 year 1 month ago
Detailed comprehensive overview of GLP-1RAs and SGLT2 inhibitors - their benefits w/ inflammatory conditions, & potential antiinflammatory effects. Bi-directional interplay between obesity, inflammation, and comorbid diseases https://t.co/oAQsuWVbZO https://t.co/SNqngATBtv
Dr. John Cush RheumNow
1 year 1 month ago
Rheumatic Dz & HIV
- Arthralgia: self limiting
- HIV-assoc arthritis: mimics RA
- Occurs w/ HIV: SpA, ReA, PsA
- Less : IIM, vasculitis, opportunistic infxn https://t.co/Yf7jZ0icZw https://t.co/6FuJgvDYRF
Dr. John Cush RheumNow
1 year 1 month ago
Medscape overview of Polymyositis has been updated - good click and learn! https://t.co/Utx389l7KP https://t.co/Nx9pPiBsMx
Dr. John Cush RheumNow
1 year 1 month ago
Cohort study of 1,553 Biologic or JAKi Rx IBD (Crohns; UC) pts (SpA excluded) found 106 (6.8%) w/ MSK Sxs & 30 (1.9%) later Dx w/ SpA (20: axial, 10: peripheral) after median F/U 5.2 yrs. SpA risk factors: partial Mayo UC (HR 1.57) & HLA-B27 positivity (HR 3.70) https://t.co/WgLLUjlLMk
Dr. John Cush RheumNow
1 year 1 month ago
The world of rheumatoid arthritis treatment has changed dramatically. What do the experts say about the evolution of biologics and DMARDs over the last 20 years?
Join us for a live webinar, moderated by Dr. Jack Cush, where we'll unpack the results of a nationwide survey.
Tues, https://t.co/pKhuHPwcs0

